PLoS One:FGFR1诱导肿瘤上皮间质转化机制

2012-07-02 Beyond 生物谷

上皮-间质转化(epithelial mesenchymal transitions,EMT)是指上皮细胞在形态学上发生向成纤维细胞或间充质细胞表型的转变并获得迁移的能力。EMT是胚胎发育中的一个基本过程,它使在特殊部位产生的上皮细胞从上皮组织分离并迁移到其他位置,是正常发育、伤口愈合以及恶性上皮肿瘤发生的基础。 肿瘤浸润和转移是癌症死亡的最常见的原因。上皮型肿瘤细胞侵入周围组发生转移,其中上皮

上皮-间质转化(epithelial mesenchymal transitions,EMT)是指上皮细胞在形态学上发生向成纤维细胞或间充质细胞表型的转变并获得迁移的能力。EMT是胚胎发育中的一个基本过程,它使在特殊部位产生的上皮细胞从上皮组织分离并迁移到其他位置,是正常发育、伤口愈合以及恶性上皮肿瘤发生的基础。

肿瘤浸润和转移是癌症死亡的最常见的原因。上皮型肿瘤细胞侵入周围组发生转移,其中上皮间质转化是必需的。近日,发表在PLoS On杂志上的一则研究证明FGFR1在膀胱癌中的表达是增加的,FGFR1的激活诱导上皮癌(UC)细胞株发生EMT。

研究人员在体外创建了FGFR1诱导的EMT模型,并用这个模型来研究尿路上皮肿瘤的EMT过程。FGFR1的激活促进了72小时内的EMT。最初肌动蛋白应力纤维出现快速增长,细胞大小增加,肿瘤细胞形态发生改变,迁移和侵袭增加。

通过定点突变和小分子抑制剂证明,有丝分裂原活化蛋白激酶(MAPK)和磷脂酶C伽玛(PLCγ)途径调节EMT过程。肌动蛋白应力纤维的形成受PLCγ激活,对细胞大小增加,迁移和改变形态非常重要。MAPK的活化调控迁移和E-cadherin表达,表明PLCγ和MAPK的联合激活对一个完整的EMT是需要的。

接下来,研究者采用芯片微列陈评估这些信号级联的下游基因表达的变化。发现FGFR1上调COX-2,造成细胞内前列腺素E(2)水平的增加,促进迁移。总之,研究数据证明,在上皮癌(UC)细胞株中,FGFR1的激活通过协调多个信号通路的激活,促进前列腺素合成激活,促进EMT。

doi:10.1371/journal.pone.0038972
PMC:
PMID:

FGFR1-Induced Epithelial to Mesenchymal Transition through MAPK/PLCγ/COX-2-Mediated Mechanisms

Darren C. Tomlinson,1 Euan W. Baxter,1 Paul M. Loadman,2 Mark A. Hull,3 and Margaret A. Knowles1,*

Tumour invasion and metastasis is the most common cause of death from cancer. For epithelial cells to invade surrounding tissues and metastasise, an epithelial-mesenchymal transition (EMT) is required. We have demonstrated that FGFR1 expression is increased in bladder cancer and that activation of FGFR1 induces an EMT in urothelial carcinoma (UC) cell lines. Here, we created an in vitro FGFR1-inducible model of EMT, and used this model to identify regulators of urothelial EMT. FGFR1 activation promoted EMT over a period of 72 hours. Initially a rapid increase in actin stress fibres occurred, followed by an increase in cell size, altered morphology and increased migration and invasion. By using site-directed mutagenesis and small molecule inhibitors we demonstrated that combined activation of the mitogen activated protein kinase (MAPK) and phospholipase C gamma (PLCγ) pathways regulated this EMT. Actin stress fibre formation was regulated by PLCγ activation, and was also important for the increase in cell size, migration and altered morphology. MAPK activation regulated migration and E-cadherin expression, indicating that combined activation of PLCγand MAPK is required for a full EMT. We used expression microarrays to assess changes in gene expression downstream of these signalling cascades. COX-2 was transcriptionally upregulated by FGFR1 and caused increased intracellular prostaglandin E2 levels, which promoted migration. In conclusion, we have demonstrated that FGFR1 activation in UC cells lines promotes EMT via coordinated activation of multiple signalling pathways and by promoting activation of prostaglandin synthesis.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1704937, encodeId=e1531e0493746, content=<a href='/topic/show?id=7b3c20040c8' target=_blank style='color:#2F92EE;'>#上皮间质转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20040, encryptionId=7b3c20040c8, topicName=上皮间质转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9530903442, createdName=limedical1984, createdTime=Wed Apr 24 23:09:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789444, encodeId=ce491e89444ff, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Aug 07 17:09:00 CST 2012, time=2012-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483054, encodeId=e5a0148305449, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Wed Jul 04 09:09:00 CST 2012, time=2012-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534194, encodeId=dbea1534194fd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Wed Jul 04 09:09:00 CST 2012, time=2012-07-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1704937, encodeId=e1531e0493746, content=<a href='/topic/show?id=7b3c20040c8' target=_blank style='color:#2F92EE;'>#上皮间质转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20040, encryptionId=7b3c20040c8, topicName=上皮间质转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9530903442, createdName=limedical1984, createdTime=Wed Apr 24 23:09:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789444, encodeId=ce491e89444ff, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Aug 07 17:09:00 CST 2012, time=2012-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483054, encodeId=e5a0148305449, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Wed Jul 04 09:09:00 CST 2012, time=2012-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534194, encodeId=dbea1534194fd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Wed Jul 04 09:09:00 CST 2012, time=2012-07-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1704937, encodeId=e1531e0493746, content=<a href='/topic/show?id=7b3c20040c8' target=_blank style='color:#2F92EE;'>#上皮间质转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20040, encryptionId=7b3c20040c8, topicName=上皮间质转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9530903442, createdName=limedical1984, createdTime=Wed Apr 24 23:09:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789444, encodeId=ce491e89444ff, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Aug 07 17:09:00 CST 2012, time=2012-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483054, encodeId=e5a0148305449, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Wed Jul 04 09:09:00 CST 2012, time=2012-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534194, encodeId=dbea1534194fd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Wed Jul 04 09:09:00 CST 2012, time=2012-07-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1704937, encodeId=e1531e0493746, content=<a href='/topic/show?id=7b3c20040c8' target=_blank style='color:#2F92EE;'>#上皮间质转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20040, encryptionId=7b3c20040c8, topicName=上皮间质转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9530903442, createdName=limedical1984, createdTime=Wed Apr 24 23:09:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789444, encodeId=ce491e89444ff, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Aug 07 17:09:00 CST 2012, time=2012-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483054, encodeId=e5a0148305449, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Wed Jul 04 09:09:00 CST 2012, time=2012-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534194, encodeId=dbea1534194fd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Wed Jul 04 09:09:00 CST 2012, time=2012-07-04, status=1, ipAttribution=)]
    2012-07-04 liuyiping

相关资讯

PLoS ONE:乳腺癌复发的新鉴定指标

近日,IMIM研究所的研究人员证实乳腺癌细胞中14-3-3蛋白sigma与肿瘤细胞激活NF-kB蛋白复合物的能力有直接联系,NF-kB的激活关系到肿瘤进展。肿瘤中NF-kB的活化情况也被确定为乳腺癌患者复发的最佳指标。研究人员还介绍了一组乳腺癌细胞中以及其他;类型肿瘤细胞中被激活的于肿瘤预后较差相关的基因。 早期研究发现14-3-3蛋白sigma不存在于许多乳腺癌患者体内。现在研究发现这种蛋白质

PLoS Biol :多巴胺在睡眠调节中的作用

近日,西班牙研究人员发现神经递质多巴胺调节睡眠的新功能。相关研究论文发表在PLoS Biology杂志上。 多巴胺是一种神经传导物质,用来帮助细胞传送脉冲,主要负责大脑的情欲,感觉,将兴奋及开心的信息传递,也与上瘾有关。 去甲肾上腺素是一种神经递质,主要由交感节后神经元和脑内肾上腺素能神经末梢合成和分泌,是后者释放的主要递质,也是一种激素,由肾上腺髓质合成和分泌,但含量较少。循环血液中的去甲肾

PLoS One:姜黄素抗小细胞肺癌机制

姜黄(Curcuma longa)是姜科植物姜黄的根茎,姜黄不仅在印度作为香料用于食品咖喱中,而且在中国具有悠久的药用历史,其性味辛、苦、温,可行气破瘀、通经止痛。姜黄主要成分姜黄素具有广泛的药理作用,而对于姜黄素抗肿瘤作用的研究,长期以来主要集中在肿瘤的化学预防方面。随着现代分子生物学研究的不断发展,研究者们对姜黄素作用机制有了更深入的研究。 虽然已有大量文献证实姜黄素可以防止癌变,抑制肿

PLoS ONE:发现新的肺动脉高压治疗策略

肺动脉高压是各种原因引起的静息状态下右心导管测得的肺动脉平均压(mean pulmonary arterial pressure,mPAP)≥25mmHg的一组临床病理生理综合征。由于肺血管重塑引起肺循环血流动力学改变,最终可导致右心衰竭,甚至死亡。 近日,来自美国新泽西医学院的研究人员首次发现了肺动脉高压新的用药靶点--平滑肌肌球蛋白,还发现平滑肌肌球蛋白的抑制剂CK-2019165(CK-1

PLoS ONE:埃可病毒诱导神经元细胞死亡的机制

埃可30型肠道病毒(Echo30)能够引起无菌性脑膜炎,是目前研究得较热的人类肠道病毒(EVs)之一。目前,由Echo30感染所引起的显著临床结果的潜在机制还不明确。 近日,来自韩国国家卫生研究院的研究人员Doo-Sung Cheon发现,通过激活TRIO-RhoA信号,Echo30诱导了神经元细胞的死亡。相关论文发表在5月7日的PLoS ONE。 该研究的目的在于阐明Echo30感染所引起的

PLoS ONE:缺氧调节的溶瘤腺病毒基因治疗

6月15日,PLoS ONE在线报道了缺氧调节溶瘤腺病毒治疗肿瘤的研究进展。缺氧是一个微环境因素,有助于肿瘤细胞的侵袭,进展和转移。缺氧肿瘤细胞往往会比常氧肿瘤细胞表现出更大的放化疗抵抗能力。这表明人类需要新型抗癌疗法有效地消除缺氧肿瘤细胞。 以往研究发明了肿瘤特异的复制性溶瘤腺病毒(OBP-301:Telomelysin)。其中,人端粒酶逆转录酶(hTERT)启动子驱动病毒E1的表达。 hTE